查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967623

表皮生長因子受體非小細胞肺癌市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、通路、地區和競爭格局分類，2021-2031年

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel,By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球表皮生長因子受體 (EGFR) 陽性非小細胞肺癌市場預計將從 2025 年的 2.1458 億美元成長到 2031 年的 3.2638 億美元，複合年成長率為 7.24%。

此領域包含旨在抑制 EGFR 蛋白的標靶治療，EGFR 蛋白是攜帶特定基因突變患者腫瘤生長的主要促進因素。市場成長主要受精準腫瘤學應用日益廣泛以及分子診斷融入標準治療的推動。根據 2024 年國際肺癌研究協會 (IASLC) 的數據，67% 的受訪者估計其所在地區超過一半的肺癌患者目前正在接受生物標記檢測，這一趨勢透過識別需要此類檢測的患者群體，正在提升市場潛力。

市場概覽
預測期 2027-2031
市場規模：2025年 2.1458億美元
市場規模：2031年 3.2638億美元
複合年成長率：2026-2031年 7.24%
成長最快的細分市場 Erlotinib
最大的市場 北美洲

然而，新一代療法的高成本構成了市場准入的重大障礙。先進的蛋白酪氨酸激酶抑制劑價格高昂，往往超出發展中國家醫療體系的報銷限額，限制了經濟敏感地區病患的用藥機會。這種經濟障礙嚴重阻礙了中低收入國家市場的擴充性，進而限制了這些標準療法在全球的推廣和應用。

市場促進因素

全球非小細胞肺癌發生率的上升是市場成長的主要驅動力，也使得大規模治療方案的需求變得特別迫切。隨著患者數量的增加，醫療系統必須優先保障標靶表皮生長因子受體抑制劑的供應，以有效控制腫瘤進展。根據美國癌症協會發布的《2024年癌症事實與數據》報告，預計光是2024年美國就將新增約234,580例肺癌和支氣管癌病例。日益加重的疾病負擔將直接推動對分子標靶療法的需求成長，並隨著診斷通訊協定的改進，更多符合標準治療條件的患者湧入市場，從而促進商業性擴張。

同時，新一代蛋白酪氨酸激酶抑制劑的快速發展正在克服突變陽性患者獲得性抗藥性的挑戰。製藥公司正積極加強其臨床研發管線，以證明第三代藥物在可切除和轉移性疾病中的卓越療效。例如，Astra Zeneca在2024年6月發布的新聞稿中公佈了LAURA III期臨床試驗的結果，強調泰瑞沙（Tagrisso）與安慰劑相比，顯著降低了不可切除的III期EGFR突變陽性非小細胞肺癌（NSCLC）患者的疾病進展或死亡風險達84%。這項成功凸顯了這些治療方法的經濟價值，並進一步證明了先進治療方法的廣泛市場應用，正如Astra Zeneca2024年報告所顯示，其旗艦抑制劑的收入已達58億美元。

市場挑戰

新一代療法的高昂成本是全球表皮生長因子受體陽性非小細胞肺癌市場成長的主要障礙。先進的蛋白酪氨酸激酶抑制劑價格仍然昂貴，往往超出醫療系統的報銷能力，尤其是在對成本高度敏感的經濟體中。這種經濟差距實際上阻礙了中低收入國家大量合格的患者獲得這些必要的治療，從而嚴重阻礙了市場擴張，並最終限制了這些標靶治療在全球範圍內的商業性化應用。

此外，這種經濟壓力直接阻礙了市場發展所需的臨床通訊協定的採納。根據國際肺癌研究協會 (IASLC) 2024 年的一項全球調查，27.2% 的醫療專業人員認為成本是實施最佳生物標記驅動醫療的主要障礙。這項數據凸顯了資金限制如何直接阻礙市場滲透，因為治療體系相關的高成本阻礙了精準腫瘤學在全球有效惠及病患。

市場趨勢

聯合治療作為第一線治療方案，正逐漸成為治療常見EGFR突變患者的變革性標準，將治療模式從單一治療轉向更積極的多藥物聯合治療。這種轉變旨在透過在診斷後立即針對共存的致癌性路徑來延緩抗藥性的產生並延長生存期，其中無需化療的雙特異性抗體聯合治療尤其具有前景。例如，強生公司在其2025年3月發布的III期MARIPOSA試驗新聞稿中報告稱，Rybrevant和Lazcluze聯合治療在3.5年時達到了56%的生存率。這比現有標準治療（單藥治療）的44%存活率有了顯著提高。

此外，在蛋白酪氨酸激酶抑制劑（TKI）治療中擴大使用抗體藥物複合體（ADC）可以滿足初始標靶治療後疾病進展患者的重大未滿足需求。鑑於抗藥性機制不可避免地出現，ADC 透過將細胞毒性有效載荷遞送至表達特定表面抗原（如 TROP2 和 HER3）的癌細胞，有效繞過耗竭的激酶抑制通路，從而提供了一種強力的挽救性治療選擇。根據發表於 2025 年 1 月《應用臨床試驗》（Applied Clinical Trials）雜誌上的報導，在非鱗狀非小細胞肺癌患者中，與多西他賽相比，達托泊單抗德魯替康可使疾病進展或死亡風險降低 37%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：表皮生長因子受體在非小細胞肺癌的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（Erlotinib、Afatinib、Gefitinib、Osimertinib、Dacomitinib）
    • 分銷通路（線上、線下）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美表皮生長因子受體非小細胞肺癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲表皮生長因子受體非小細胞肺癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區表皮生長因子受體非小細胞肺癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲非小細胞肺癌表皮生長因子受體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲非小細胞肺癌表皮生長因子受體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球表皮生長因子受體非小細胞肺癌市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Genentech, Inc.
  • Astellas Pharma Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20183

The Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market is projected to increase from USD 214.58 Million in 2025 to USD 326.38 Million by 2031, expanding at a CAGR of 7.24%. This sector consists of specialized targeted therapies aimed at inhibiting the EGFR protein, a key driver of tumor growth in patients with specific genetic mutations. Market growth is primarily fueled by the increasing use of precision oncology and the integration of molecular diagnostics into standard care. Data from the International Association for the Study of Lung Cancer in 2024 revealed that 67% of survey respondents estimated over half of lung cancer patients in their regions are now undergoing biomarker testing, a trend that boosts market potential by identifying the necessary patient pool.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 214.58 MIllion
Market Size 2031USD 326.38 MIllion
CAGR 2026-20317.24%
Fastest Growing SegmentErlotinib
Largest MarketNorth America

However, the market faces a substantial obstacle due to the high costs associated with next-generation therapeutic agents. The steep pricing of advanced tyrosine kinase inhibitors often surpasses reimbursement limits within developing healthcare systems, restricting patient access in economically sensitive regions. This financial barrier significantly hinders market scalability in low- and middle-income nations, thereby limiting the global distribution and adoption of these standard-of-care treatments.

Market Driver

The increasing global incidence of Non-Small Cell Lung Cancer serves as a major driver for market growth, creating a critical need for scalable therapeutic solutions. As patient numbers rise, healthcare systems must prioritize acquiring targeted epidermal growth factor receptor inhibitors to effectively manage tumor progression. The American Cancer Society's 'Cancer Facts & Figures 2024' report projected approximately 234,580 new diagnoses of lung and bronchus cancer in the United States alone for that year. This growing disease burden directly necessitates a higher volume of molecularly targeted agents, sustaining commercial expansion as improved diagnostic protocols identify more candidates eligible for standard treatments.

Concurrently, the rapid advancement of next-generation tyrosine kinase inhibitors is overcoming the challenge of acquired drug resistance in mutation-positive patients. Pharmaceutical companies are actively enhancing clinical pipelines to prove the superior efficacy of third-generation agents in both resectable and metastatic scenarios. For instance, AstraZeneca's June 2024 press release regarding the 'LAURA Phase III Trial Results' highlighted that Tagrisso significantly reduced the risk of disease progression or death by 84% compared to a placebo in unresectable Stage III EGFR-mutated NSCLC. This success underlines the economic value of these therapies, further evidenced by AstraZeneca's 2024 report citing $5.8 billion in revenue from its flagship inhibitor, demonstrating the widespread market adoption of advanced biological treatments.

Market Challenge

The exorbitant cost of next-generation therapeutic agents represents a major hurdle limiting the growth of the Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market. Advanced tyrosine kinase inhibitors maintain high price points that often outstrip the reimbursement capacities of healthcare systems, especially within cost-sensitive economies. This financial gap creates a significant barrier to market scalability by effectively preventing a large portion of eligible patients in low- and middle-income countries from accessing these essential treatments, thereby restricting the global commercial reach of such targeted interventions.

Furthermore, this economic pressure directly impedes the adoption of clinical protocols necessary for market development. According to a 2024 global survey by the International Association for the Study of Lung Cancer, 27.2% of healthcare professionals cited cost as the main impediment to implementing optimal biomarker-driven care. This statistic highlights how financial constraints directly obstruct market penetration, as the high costs associated with the treatment ecosystem hinder the effective delivery of precision oncology to patients on a global scale.

Market Trends

First-line combination therapies are emerging as a transformative standard for treating patients with common EGFR mutations, moving the paradigm from monotherapy toward more aggressive multi-agent regimens. This shift aims to delay resistance and prolong survival by targeting concurrent oncogenic pathways immediately upon diagnosis, with chemotherapy-free bispecific antibody combinations showing particular promise. For example, Johnson & Johnson reported in a March 2025 press release for the 'Phase III MARIPOSA Trial' that the combination of Rybrevant and Lazcluze resulted in a 56% survival rate at 3.5 years, compared to 44% for patients treated with the existing standard-of-care monotherapy.

Additionally, the increasing use of antibody-drug conjugates (ADCs) in post-TKI settings is addressing significant unmet needs for patients whose disease progresses following initial targeted therapy. As resistance mechanisms inevitably arise, ADCs provide a potent salvage option by delivering cytotoxic payloads to tumor cells expressing specific surface antigens like TROP2 or HER3, effectively bypassing exhausted kinase inhibition pathways. According to a January 2025 article in Applied Clinical Trials regarding the 'TROPION-Lung05 and TROPION-Lung01 Trials,' datopotamab deruxtecan reduced the risk of disease progression or death by 37% in non-squamous non-small cell lung cancer patients compared to docetaxel.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Genentech, Inc.
  • Astellas Pharma Inc

Report Scope

In this report, the Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market, By Drug Type

  • Erlotinib
  • Afatinib
  • Gefitinib
  • Osimertinib
  • Dacomitinib

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market, By Distribution Channel

  • Online
  • Offline

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market.

Available Customizations:

Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Erlotinib, Afatinib, Gefitinib, Osimertinib, Dacomitinib)
    • 5.2.2. By Distribution Channel (Online, Offline)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. AstraZeneca plc.
  • 15.4. Pfizer Inc.
  • 15.5. Novartis AG
  • 15.6. Johnson & Johnson Services, Inc.
  • 15.7. Takeda Pharmaceutical Company Limited
  • 15.8. AbbVie Inc.
  • 15.9. Genentech, Inc.
  • 15.10. Astellas Pharma Inc

16. Strategic Recommendations

17. About Us & Disclaimer